论文部分内容阅读
目的探讨在体外骨髓间充质干细胞(MSC)治疗再生障碍性贫血(AA)的机制。方法2003-02~2005-04安徽医科大学第一附属医院血液内科从人骨髓分离培养MSC,用尼龙棉柱分离T淋巴细胞。分别以不同数量MSC加入到植物血凝素(PHA)刺激的AA患者T淋巴细胞增殖体系中,用MTT还原法测定MSC对AA患者T细胞增殖的影响,通过流式细胞术计算CD3+T细胞CD25(IL-2R)的表达率。结果当MSC为2×104/孔(A组)和1×104/孔(B组)时,与单独培养的AA患者T淋巴细胞(对照组)相比,MSC对AA患者T淋巴细胞增殖及CD25的表达呈明显抑制作用,差异有统计学意义(P<0·01)。当MSC为1×103/孔(C组)时,无统计学意义。结论MSC抑制AA患者T细胞的活化与增殖,且这种抑制作用具有数量依赖性。
Objective To investigate the mechanism of ameliorating bone marrow mesenchymal stem cells (MSCs) in treating aplastic anemia (AA) in vitro. Methods From February 2003 to April 2005, Department of Hematology, the First Affiliated Hospital of Anhui Medical University isolated MSC from human bone marrow and isolated T lymphocytes with nylon cotton column. The cells were added into T lymphocyte proliferation system of AA patients stimulated with phytohaemagglutinin (PHA) by different numbers of MSCs respectively. The effects of MSC on T cell proliferation in AA patients were determined by MTT reduction method. CD3 + T cells were counted by flow cytometry CD25 (IL-2R) expression rate. Results When MSCs were 2 × 10 4 / well (group A) and 1 × 10 4 / well (group B), compared with T lymphocytes from AA patients (control group) CD25 expression was significantly inhibited, the difference was statistically significant (P <0.01). When MSC was 1 × 103 / well (group C), there was no statistical significance. Conclusion MSC can inhibit the activation and proliferation of T cells in AA patients in a dose-dependent manner.